This study aimed to evaluate the treatment outcomes, including pathological complete response (pCR) and disease-free survival, of HER2-directed therapies in patients with non-metastatic HER2-positive BC in resource-limited settings. This evidence concerns the gene ERBB2 and breast cancer.